Zinc-ing about diabetes

ZNT8 burst onto the scene in 2007 as a promising target for type 2 diabetes, and follow-up studies suggested that stimulating the zinc transporter protein could have therapeutic benefit.^1,2 But a new study suggests that the preferred approach might be to inhibit the target.³

Because of the conflicting data, researchers say that more studies are needed to flesh out the functional consequences of expression of ZNT8 (solute carrier family 30 zinc transporter member 8; SLC30A8) and its variants before embarking on drug discovery efforts...